Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L27/52—Hydrogels or hydrocolloids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/14—Macromolecular materials
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/14—Macromolecular materials
  • A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/14—Macromolecular materials
  • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
  • C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
  • C08J7/12—Chemical modification
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
  • C08L101/00—Compositions of unspecified macromolecular compounds
  • C08L101/005—Dendritic macromolecules
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
  • C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
  • C08L33/24—Homopolymers or copolymers of amides or imides
  • C08L33/26—Homopolymers or copolymers of acrylamide or methacrylamide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
  • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
  • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
  • A61L2300/622—Microcapsules
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2400/00—Materials characterised by their function or physical properties
  • A61L2400/06—Flowable or injectable implant compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2430/00—Materials or treatment for tissue regeneration
  • A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction

Definitions

• the invention relates to a hybrid heterogeneous hydrogel and more particularly to its use as a filling implant.
• the lesion by compression or by any other vertebral-medullary impact evolves by neurodegenerative phenomena which develop centrifugally from the epicenter of the lesion and which gradually lead to the chronic stage of the initial lesion.
• the lesion is represented by a cystic cavity, partitioned and circumscribed by heterogeneous scar tissue composed of glial cells, fibroblasts, pericytes and meningeal cells, molecules of the extracellular matrix, in particular proteoglycans and collagen.
• This form of scarring like the intramedullary cavity, is the cause of failure in the regeneration of the nerve fibers of the ascending and descending axonal pathways.
• Regenerative therapies aim at cellular repair of the cystic cavity at the chronic stage of spinal cord trauma as well as revascularization of the damaged area which can represent a significant loss of volume, the size of which varies from 2 to 6 vertebral bodies in height.
• Regenerative therapies also aim to regrow nerve fibers through this cystic cavity in order to promote the reconnection of spinal neuronal circuits, and restore locomotor and sensory functions. This strategy takes into account the post-lesional plasticity of the nervous system which is in the capacity of reforming relay circuits between the regrowing nerve fibers and intact neurons under lesions.
• the strategy used in tissue engineering is to introduce a porous and permissive substrate at the level of the lesion (either at the acute stage or at the chronic stage) to serve as a physical, chemical and mechanical support for the endogenous processes of cell, vascular and nervous repair leading to to the histological reconstruction of nervous tissue.
• the supports generally used at the experimental level and in clinical trials are represented by the particular class of biomaterials, hydrogels. They are matrices of polymers forming a crosslinked macromolecular network saturated with water. They are used in tissue engineering, especially in the nervous system. They are prepared from degradable or bioresorbable polymers to constitute temporally unstable porous structures. These polymers are of natural origin: alginate, agarose, chitosan, collagen, hyaluronic acid, fibrin, peptides or synthetic such as poly caprolactones, poly (hydroxybutyrates), poly (ortho esters), poly (a-hydroxy esters) ), polyanhydrides. Thus, degradable and / or bioresorbable hydrogels have been proposed to promote nerve regeneration of lesions of the spinal cord in experimental models or in clinical trials in humans.
• Biodegradable hydrogels are those which, once introduced into a living organism, decompose by spontaneous chemical hydrolysis for polyanhydrides, poly (ortho esters), poly (a-hydroxy esters). Thioether- esters break down in the presence of water and biological polymers (oligopepetides, proteins, polysaccharides) break down by the action of enzymes or other proteins produced by cells.
• US Pat. No. 7,163,545 discloses a poly (lactic-co-glycolic) acid matrix, including guide channels for axonal regeneration in combination with therapeutic agents.
• US Patent 8,377,463 teaches a device formed of poly (lactic-co-glycolic acid) to treat the acute stage of spinal cord injury which degrades in situ between 30 and 60 days, which can be combined with therapeutic agents and / or stem cells.
• Document US 2018/0037865 describes a complex hydrogel comprising a degradable matrix of hyaluronic acid, collagen, fibrins, chitosan, methycellulose, poly (ethylene oxide) or a combination thereof, combined with stem cells and therapeutic molecules, which degrade in situ at a variable rate depending on the nature of the polymer.
• Document US 20060002978 discloses a tubular matrix containing a porous polymeric material formed from homo- or copolymers of lactic acid and / or glycolic acid and / or poly (caprolactone).
• the polymer matrix can comprise an aliphatic polyester, a polyanhydride, a polyphosphazene, a polyvinyl alcohol, a polypeptide, an alginate.
• 8,877,498 teaches a matrix comprising a hierarchical structure with aligned topographic channels and ridges along the walls allowing guided regeneration of nerve fibers, and the composition of which comprises chitosan, chitin, cellulose, l alginate, gelatin, hyaluronic acid, collagen, elastin or a combination thereof.
• Document WO2014013188 discloses an acetylated chitosan biomaterial in the form of a suspension of microgels or in the form of a 2 to 3 mm 3 gel for treating lesions of the spinal cord.
• the documents US 2015/0166786 A1 and WO2013010087A1 disclose a hydrogel composed of poly (lactic-co-glycolic) or comprising poly (s-caprolactone) combined with poly (L-lysine) for treating acute lesions of the spinal cord in humans.
• Document US 2015/0044259 A1 describes a matrix composed of poly-D Lysine and a peptidoglycan to promote the growth of nerve fibers.
• Document EP2347763A1 and document US 2011/0177170 A1 describe a matrix composed of collagen microparticles included in a homogeneous gel composed of peptides, uronic acid and hexosamine for implantation together with a cell transplant in the treatment of lesions of the system.
• Document WO2013 / 084137 discloses an implant degradable from hemihydrated calcium sulfate which includes channels of parallel geometry combined with a growth factor for the treatment of complete lesions of the spinal cord in humans.
• Biodegradable hydrogels are also proposed such as those presented in document US 8,815,277 or in document WO2011 / 002249. These systems are said to have the advantage of not being invasive, that is, they do not require open surgery of the spinal cord for their implantation. Typically, these systems degrade in situ within two weeks, which is very rapid compared to a regenerative process.
• hydrogel based on poly (lactic-co-glycolic) acid for repairing nerve pathways in the spinal cord.
• This hydrogel degrades in 30 to 60 days in rats, which is a very insufficient time for successful tissue regeneration if these results are transposed to humans.
• a comparative study has shown that the growth delay of isolated axons is longer and the rate of regeneration is three times slower in humans compared to rats (Gordon 2007, The potential of electrical stimulation to promote functional recovery after peripheral nerve injury -comparisons between rats and humans; Acta Neurochir Suppl. 2007; 100: 3-11).
• the duration is even greater because a large number of nerve fibers must grow back to ensure functional motor recovery.
• degradable hydrogel matrices are degraded by breaking polymer chains simultaneously with the migration and colonization of cells, blood vessels, nerve fibers in regrowth during tissue remodeling.
• the degradable hydrogel matrices exhibit a high rate of degradation leading to a rapid loss of the initial mechanical properties of the support.
• tissue regeneration to be optimal, that is to say complete over time, it is essential that the hydrogel support maintains throughout the tissue remodeling process a certain structural integrity in space and time. It also appears that the hydrolysis of the ester bonds of poly ( ⁇ -hydroxy acids) releases acidic compounds which, by accumulating in the graft site, decrease the pH.
• WO2010 / 097524 discloses a hybrid heterogeneous hydrogel which is a copolymer derived from the following monomers: - a dendrimer monomer comprising a central nucleus A, macromolecular dendritic branches of poly (oxyethylene) and at least one of the dendritic branches functionalized with an acrylate or methacrylate radical,
• bioactive copolymerizable material chosen from the group consisting of a derivative of a complex sugar, a derivative of a tissue adhesion peptide and a derivative of a polymer conjugate coupled to antibodies directed against lipid derivatives
• An object of the invention consists in alleviating these drawbacks, and more particularly in providing an implant based on a hydrogel, the rate of degradation of which is reduced in comparison with the hydrogels of the prior art and which adapt better to mechanical stresses. linked to cell colonization.
• a hybrid heterogeneous hydrogel formed by means of a copolymer derived from at least three of the following monomers:
• an acrylamide compound chosen from an N-substituted methacrylamide and an N-substituted acrylamide
• the heterogeneous hybrid hydrogel characterized in that the hybrid heterogeneous hydrogel is formed mainly by a plurality of microbeads having a diameter greater than 1.5 microns and less than 10 microns and containing predominantly by weight the N-substituted methacrylamide and N- acrylamide substituted, the microspheres being assembled to each other to form aggregates containing between 5 and 50 microbeads, the aggregates being linked to each other by crosslinking points to define a through porous network defining three-dimensional percolating paths, the through porous network defining pores of which the majority of the porous fraction is formed by pores whose diameter is between 10 and 30 microns and in which the hybrid heterogeneous hydrogel has a viscoelastic character and has a elastic modulus between 1 and 200kPa.
• the microbeads have a diameter between 2 and 5 microns.
• the microbeads comprise at least 90% by weight of the acrylamide compound. Even more preferably, the microbeads consist of the crosslinked acrylamide compound.
• the aggregates contain between 10 and 30 microbeads. It is advantageous to provide that the aggregates are deformable in compression.
• the functionalized dendrimer monomer comprises one or more macromolecular dendritic branches of poly (ethylene oxide), said at least one macromolecular dendritic branches of poly (ethylene oxide) being functionalized by one or more bioactive copolymerizable materials chosen from the group consisting of a derivative of a complex sugar, a derivative of a tissue adhesion peptide and a derivative of a polymer conjugate coupled to antibodies directed against lipid derivatives said one or more bioactive copolymerizable materials covering the wall of the three-dimensional percolating network.
• the wall of the three-dimensional percolating network is functionalized by means of several different bioactive copolymerizable materials.
• said one or more active molecules are selected from the group consisting of a derivative of complex sugars, derivatives of tissue adhesion peptide or peptide with angiogenic activity, derivatives of peptide stimulating blood.
• nerve regrowth derived from peptide stimulating cell proliferation and differentiation, a derivative of a polymer conjugate coupled to antibodies directed against lipid derivatives, chemokines of the class of Stromal-derived factor- 1 (SDF-1 ).
• the functionalized dendrimer monomer comprises a central nucleus A, macromolecular dendritic branches of poly (ethylene oxide) with at least one of the dendritic branches functionalized by a polymerizable acrylate or methacrylate radical.
• the acrylamide compound is N- (2-hydroxypropyl) methacrylamide (HPMA) and the functionalized dendrimer monomer comprises dendritic branches of poly (ethylene oxide) functionalized at their periphery with bioactive agents conferring bioactive properties. for tissue regeneration.
• HPMA N- (2-hydroxypropyl) methacrylamide
• the functionalized dendrimer monomer comprises dendritic branches of poly (ethylene oxide) functionalized at their periphery with bioactive agents conferring bioactive properties. for tissue regeneration.
• Another object of the invention consists in the use of a hybrid heterogeneous hydrogel according to one of the preceding configurations as a filling implant intended to be interposed between the edges of an anatomical defect of an organ or of a tissue.
• the hybrid heterogeneous hydrogel as a filling implant is used to fill an intra-parenchymal cavity of the central nervous system.
• the hybrid heterogeneous hydrogel as a filler implant is used to correct the congenital malformation of the central nervous system or spina bifida.
• a method of manufacturing a hybrid heterogeneous hydrogel which is easy to implement for industrial production, allowing the production of hybrid heterogeneous hydrogels better suited to the formation of an implant. filling and in particular as regards the physicochemical specifications.
• the process for making a heterogeneous hybrid hydrogel is remarkable in that it includes:
• an acrylamide compound chosen from an N-substituted methacrylamide and N-substituted acrylamide
• the microspheres having a diameter greater than 1.5 microns and less than 10 microns and containing predominantly by weight of N-substituted methacrylamide and N-substituted acrylamide,
• the microbeads being assembled to each other to form aggregates containing between 5 and 50 microbeads, the aggregates being linked to each other by crosslinking points to define a hybrid heterogeneous hydrogel delimiting a porous network crossing defining three-dimensional percolating paths, the through porous network defining pores of which the majority of the porous fraction is formed by pores whose diameter is between 10 and 30 microns and wherein the hybrid heterogeneous hydrogel has a viscoelastic character and has an elastic modulus of between 1 and 200kPa; and in which the reaction mixture is injected into molds of sealed cylindrical shape and conductive of heat
• the molar ratio between the functionalized dendrimer monomer and the crosslinking agent is between 0.1 and 0.8.
• the functionalized dendrimer monomer has a molecular mass of between 6220 g / mol and 23280 g / mol.
• a bioactive copolymerizable material is present in the reaction mixture to form the microbeads, the bioactive copolymerizable material being chosen from the group consisting of a derivative of a complex sugar, a derivative of a tissue adhesion peptide and a derived from a polymer conjugate coupled to antibodies directed against lipid derivatives.
• the reaction mixture is injected into a metal mold, the internal walls of which are covered with polytetrafluoroethylene.
• the mold is preferably heated using a water bath.
• the polymerization of the reaction mixture is carried out at a first temperature for at least 80 minutes to form the microbeads then an increase in the temperature of the mold and of the reaction mixture of at least 5 ° C is carried out.
• the process for forming aggregates of microbeads of a hybrid heterogeneous hydrogel according to one of the preceding configurations is involved in a process for manufacturing a filling implant.
• the method of manufacturing a filling implant comprising forming aggregates of microbeads of a hybrid heterogeneous hydrogel and assembling the aggregates to each other by a three-dimensional printing process to form a filling implant.
• FIG. 1 schematically illustrates an implant provided with a heterogeneous hybrid hydrogel defining three-dimensional through channels
• FIG. 2 illustrates a metal body defining four cylindrical wells whose walls are coated with a PTFE surface.
• a hydrogel-based implant is intended to be implanted in a cavity representing a volumetric loss of tissue, for example a medullary cavity. If the rate of degradation (Vd) of the hydrogel is greater than the rate of cell regeneration (V r ), rapidly there is no longer any support for tissue reconstruction. Tissue reconstruction will be limited to the periphery of the implantation area and the cellular regeneration process will be incomplete.
• the biodegradation of the polymer scaffolds implanted in the spinal cord injury results in the physical separation between the implant body and the spinal cord tissue. The separation space between the implant and the tissue is filled with cerebrospinal fluid and prevents the integration of the hydrogel into the nerve tissue. It also prevents the regenerating axons from reaching the body of the scaffold formed by the implant.
• the rate of degradation of the polymer network of the implant is in equilibrium with the rate of tissue repair so that the decrease in the total volume of the gel with the increasing volume of the growing cell bioburden remains constant so as not to impose compressive mechanical stresses at the interfaces with the host organ. Such stresses would cause ischemic compression injury.
• the process of cell regeneration and the process of implant degradation begin from the interface in contact with the spinal cord and extend into the interior of the cavity.
• the center of the hydrogel matrix does not completely degrade and remains in the form of oligomeric chains which have lost their structure and function as a growth substrate.
• the implant is no longer usable because it does not provide any mechanical support and it ends up interfering with the reconstruction.
• Degradation of the matrix can further lead to dissociation of the connections that exist between cells that have migrated into the hydrogel structure. These connections are essential in the formation and cohesion of a functional tissue.
• the use of a hydrogel of degradable polymers as an implant in tissue engineering for the optimal repair of a loss of tissue volume and in particular of the nervous system therefore requires taking into account both changes in the mechanical behavior of the hydrogel matrix during of its use so that it maintains its structural integrity until the formation of new biological tissue and of its actual rate of degradation in vivo. This is not possible since, as it degrades, the matrix gradually loses its architectural topography and therefore its mechanical properties which are defined by its initial architecture. The structural integrity of the implant cannot be maintained over time. However, the structural stability of the implant is an essential characteristic to support the formation of tissue reconstruction during the entire tissue reconstruction.
• the nerve fibers Following an injury, the nerve fibers have a natural capacity to regenerate either by elongation or by collateral budding. This capacity is greatly reduced if the ends of the regenerating fibers, the growth cones, do not find a substrate to adhere and elongate.
• non-degradable hybrid heterogeneous hydrogel means a polymeric composition which is not subject to degradation in situ by reaction of chemical or enzymatic hydrolysis or of cleavage by photolysis, under physiological conditions representative of the human body. For example, there is little or no chemical degradation over a reference period of at least one or two years.
• the study of the degradability of the hybrid heterogeneous hydrogel is advantageously carried out at 40 ° C. in an acid solution whose pH is equal to 1 and in a basic solution whose pH is equal to 14. A piece of hydrogel is placed.
• each solution is maintained at 40 ° C, for example by means of a hot plate.
• the solution is stirred.
• the hybrid heterogeneous hydrogel sample and the solution are observed regularly. For example, it is found that after one week, a non-degradable hybrid heterogeneous hydrogel has not changed in appearance and the solution has remained clear. No floating residue of the sample is observed in the solution. There is also no loss of mass of the hydrogel.
• the acidic solution is preferably a 0.1mol / L hydrochloric acid solution.
• the basic solution is advantageously a 1 mol / L sodium hydroxide solution.
• the hybrid heterogeneous hydrogel is also analyzed by high performance liquid chromatography.
• a mixture containing 25% by volume of methanol and 75% of water is preferably used as eluent.
• the flow rate of the eluent is advantageously 1 ml / min.
• the column used can be of the C18 novapack 3.9 * 150mm type in reverse phase. The analysis of the chromatograms makes it possible to detect the degradation of the hydrogel by looking for its constituents.
• hydrogel which is not bioresorbable and which is compressible.
• a hydrogel allows its use as a filling implant and its interposition between the edges of an anatomical defect of an organ, for example of the nervous system and in particular a post-traumatic intramedullary cystic cavity
• the implant does not deteriorate or only slightly, the volume of the implant should not interfere with cell reconstruction. It is particularly advantageous to form a filling implant which comprises a porous hybrid heterogeneous hydrogel support with through pores which allow cell regeneration within the implant. As illustrated in Figure 1, it is particularly advantageous that the hybrid heterogeneous hydrogel 1 has a porous structure whose pores communicate with each other to create a percolating network 2 in the three dimensions of the volume of the gel. The through network formed by the pores allows cells to migrate and proliferate to the core of the hydrogel, to join together and survive through the transport and diffusion of nutrients necessary for cellular metabolism.
• the pore networks do not induce increased degradation of the hydrogel with stagnation of toxic or irritant molecules in the pores.
• the implant is a porous structure with open pores passing through the implant to define percolating paths in the three dimensions of the hydrogel.
• the open pores promote cell and vascular colonization from the tissue to the implant core as well as the flow of biological fluids, cell growth factors, cell repair factors and physiological nutrients through the implant.
• the passage of different fluids to through the implant facilitates the vascularization of the tissue generated in the implant.
• the implant forms a three-dimensional support matrix whose through pores guide the growth of cells, nerve fibers and blood vessels. Cell growth is better in contact with the implant than without the implant.
• the implant can only be formed by the hydrogel.
• the porous fraction of the hydrogel forming the implant is greater than 85%, more preferably at least equal to 90% and even more preferably at least equal to 92% by volume.
• the porous fraction can be calculated with a mercury porosimetry technique.
• a hybrid heterogeneous hydrogel in which the majority of the pore fraction is formed by pores whose diameter is between 10 and 30 microns.
• at least 60% of the porous fraction is formed by pores having a diameter of between 10 and 30 microns.
• at least 60% of the pore volume is made up of pores having a diameter between 10 and 30 microns.
• the fraction of the pores having a diameter of between 30 and 300 represent a larger fraction than the pores having a diameter of less than 10 microns.
• the fraction of the pores having a diameter of between 30 and 300 microns is greater than 20%, even more preferably greater than 30%.
• the fraction of pores having a diameter of between 30 and 300 microns is particularly advantageous for accommodating large biological objects such as multicellular tissues.
• the fraction of the pores having a diameter less than 10 microns is less than 15% even more preferably less than 10%.
• the heterogeneous hydrogel to contain less than 2% by volume of pores having a size of less than 1 micron in the porous network passing through. Such a distribution in the dimensions of the pores ensures the passage of the biological compounds through the implant while covering the entire dimensional spectrum of the biological compounds of a living tissue. This facilitates the use of the implant as a tissue equivalent of the organ to be repaired.
• the pores of the implant are compatible with the circulation of chemokines secreted by inflammatory cells.
• the implant configuration allows infiltration of glial cells, mesenchymal cells, stem / progenitor cells associated with leptomeninges secreting factor SDF-1 and stem / progenitor cells associated with the central channel epithelium with potential of neuronal differentiation, infiltration of blood vessels and the growth of regenerating nerve fibers.
• hybrid heterogeneous hydrogel in a material which has the property of changing the configuration of its porous network as the cell colonization or the amount of cell bioburden progresses.
• the hybrid heterogeneous hydrogel can deform under the stress applied by cell colonization and / or cell bioburden.
• the implant deforms under the pressure exerted by the cell tissue as it regenerates.
• the hydrogel must be able to deform with the mechanical stresses of the cellular bioburden, which makes it possible to keep a structure with percolating channels.
• a filling implant which comprises a support of porous and viscoelastically deformable heterogeneous hybrid hydrogel and the rate of degradation of which is sufficiently low for the hydrogel to be considered as a non-degradable hybrid heterogeneous hydrogel.
• the volume occupied by the porous implant will change as the regeneration progresses in order to adapt in part to the rate of regeneration around and in the hydrogel.
• the macromolecular skeleton of the heterogeneous hybrid hydrogel deforms at constant or substantially constant volume.
• the structure of the implant is made of a material which has an elastic modulus of between 1 and 200 KPa in order to adapt to the stress applied by the cell bioburden. The value of the elastic modulus can be measured at 50% of its deformation before rupture.
• the implant deforms depending on the mechanical stresses introduced by the cell bioburden into the implant.
• the implant deforms elastically and then viscoelastically so as not to interfere with cell growth, especially in the through channels.
• the implant retains a three-dimensional percolating network that stretches to ensure complete tissue regeneration. Once the tissue is reconstructed, the residual polymer network of the implant serves as a supportive intercellular matrix that stabilizes the new tissue formed by exerting mechanical tension.
• the surface of the implant has a significant roughness which allows good adhesion with the host tissue by increasing the contact surface between the implant and the cells of the tissue in contact, which will promote adhesion between the two media.
• the pores open on the surface of the implant and connected to the percolating network promote cell and vascular colonization to the heart of the implant from the tissue in contact at the same time as the circulation of biological fluids, cell growth factors and physiological nutrients needed by the cell.
• hybrid heterogeneous hydrogel which is a copolymer derived from at least three monomers: a dendrimer monomer functionalized with an ethylenic radical, an acrylamide monomer and a crosslinking agent.
• the hybrid heterogeneous hydrogel comprises a bioactive copolymerizable material.
• the hybrid heterogeneous hydrogel lacks a bioactive copolymerizable material. Bioactivation can be carried out subsequently on the hydrogel formed.
• the bioactive copolymerizable material is selected from the group comprising the derivatives, of a complex sugar, of a tissue adhesion peptide and of a polymer conjugate coupled to antibodies directed against lipid derivatives.
• the bioactive copolymerizable material is a methacryloyl or methacrylamide derivative of a complex sugar, of a peptide for adhesion to a tissue and of a polymer conjugate coupled to antibodies directed against lipid derivatives,
• the bioactive copolymerizable material may be a derivative, preferably methacryloyl or methacrylamide, of a complex sugar selected, for example, from glucosamine, N-acetyl-glucosamine, N-diglycidyl-glucosamine, N-acetylgalactosamine, N-acetylneuraminic acid (sialic acid) and polysialic acid.
• glucosamine N-acetyl-glucosamine, N-diglycidyl-glucosamine, N-acetylgalactosamine, N-acetylneuraminic acid (sialic acid) and polysialic acid.
• the bioactive copolymerizable material may be a derivative, preferably methacryloyl or methacrylamide, of a tissue adhesion peptide selected from tissue adhesion oligopeptides containing amino acid sequences such as Arg-Gly-Asp, Ile-Lys-Val-Ala-Val, Ala-His-Ala-Val-Ser-Glu, Tyr-lle-Gly-Ser-Arg, oligopeptide derivatives of tissue differentiation molecules, for example, bone morphogenetic proteins or proteins of the SDF-1 family (stromal cell derived factor-1), a chemokine which has the capacity to mobilize and attract endogenous stem cells which express the CXCR4 receptor and which has the capacity to stimulate the growth of axons during tissue regeneration.
• tissue adhesion peptide selected from tissue adhesion oligopeptides containing amino acid sequences such as Arg-Gly-Asp, Ile-Lys-Val-Ala-Val, Ala-
• the bioactive copolymerizable material may be a derivative, preferably methacryloyl or methacrylamide, of a polymer conjugate coupled to antibodies against myelin and its lipid derivatives associated with axons.
• the acrylamide monomer is advantageously an N-substituted methacrylamide or N-substituted acrylamide.
• the value of the elastic modulus is in part defined by the crosslinking density of the hydrogel, i.e. by the number of covalent branches between the macromolecular chains formed from the acrylamide monomer, preferably by controlling the number of covalent branches between the macromolecular chains of HPMA.
• the N-substituted methacrylamide is preferably chosen from the group consisting of N-monoalkylmethacrylamide, N, N-dialkylmethacrylamide, N-hydroxyalkylmethacrylamide, preferably N- (2-hydroxypropyl) methacrylamide (HPMA),
• N-alkyl, N-hydroxyalkylmethacrylamide, and N, N-dihydroxyalkylmethacrylamide are N-alkyl, N-hydroxyalkylmethacrylamide, and N-dihydroxyalkylmethacrylamide.
• the N-substituted acrylamide is preferably selected from the group consisting of N-monoalkylacrylamide, N-hydroxyalkylacrylamide, N, N-dialkylacrylamide, N-alkyl, N-hydroxyalkylacrylamide and N, N-dihydroxyalkylacrylamide.
• the dendrimer monomer preferably comprises a central nucleus A and macromolecular dendritic branches of poly (oxyethylene) (PEO). Only one of the dendritic branches is functionalized, advantageously in the terminal position, with an ethylenic radical.
• the ethylene radical is unsaturated in order to react with a monomer comprising at least one reactive vinyl double bond.
• the other dendritic branches are preferably terminated by a hydroxyl function and devoid of an ethylenic radical. They can also be functionalized before copolymerization with other functions such as ester or amide functions.
• the ethylenic radical is advantageously an acrylate or methacrylate radical.
• the star-shaped architecture of the dendrimer makes it possible to introduce into the hydrogel a multifunctional variable geometry to respond specifically to the multiple interactions envisaged with other materials.
• the indication that only one of the branches is functionalized corresponds to a statistical result indicating that on average, the dendrimer monomer is functionalized by a single branch provided with an unsaturated ethylenic radical.
• the hydroxyl functional groups in the hybrid heterogeneous hydrogel can be modified by attaching entities, for example, bioactive agents such as polypeptides, active ingredients, ligands, polymerizable groups or oligosaccharides.
• bioactive agents such as polypeptides, active ingredients, ligands, polymerizable groups or oligosaccharides.
• the central nucleus A is a group chosen from a carbosilane, a polycarbosilane, a polycarbosilane with a star architecture, or a group corresponding to the following formula (1): - (CH 2 ) n - Si - (CH 2 ) n- (1) where n is an integer between 1 and 20, preferably equal to 6.
• the central nucleus A is a poly (divinylbenzene).
• the dendrimer monomer corresponds to the following formula (2):
• R is H or CH3
• X and Y are integers from 1 to 100 and the sum of X + Y is a multiple of 4, and
• Z and Z ' are identical or different and between 1 and 100, and A preferably being a carbosilane, a polycarbosilane, a polycarbosilane with a star architecture, or a group corresponding to formula (1).
• the dendrimer monomer corresponds to the following formula (3):
• R is H or CH3, n being an integer between 1 and 20, preferably equal to 6, Z and Z are the same or different and between 1 and 100,
• X is equal to 1, 2 or 3 and,
• the mechanical and chemical properties of the hydrogel can also be adjusted by grafting, onto the free hydroxyl endings of the dendritic branches, functions with specific properties such as hydrophilic, hydrophobic and / or surfactant properties.
• the hydroxyl function can be easily functionalized due to the nucleophilic nature of its oxygen atom. This function is known to be easily activated, for example, by basic treatment.
• the intrinsic properties of the hybrid heterogeneous hydrogel can also be modified by varying the number of dendrimer monomers introduced into the hydrogel backbone and the nature of the central nucleus A. The number of dendritic branches determines the solubility of the macromolecule in water and organic solvents.
• the heterogeneous hybrid hydrogel is formed predominantly or consists of a plurality of microbeads which are assembled together to define the porous network passing through.
• the microbeads have a spherical or substantially spherical shape and predominantly a diameter greater than 1.5 microns and less than 10 microns.
• the microbeads mainly have a diameter of between 2 and 5 microns in order to better modulate the deformation of the channels according to the stress applied by the cell bioburden.
• the hydrogel microbeads in the form of aggregates which comprise at least 5 microbeads and less than 50 microbeads and preferably at least 10 microbeads.
• the microbeads agglomerate with one another to form aggregates in groups of 10 to 30 microbeads.
• the hydrogel microbeads it is also particularly advantageous for the hydrogel microbeads to agglomerate with one another in a so-called “bunch of grape” configuration, which facilitates the formation of an effective porous network while ensuring good deformability of the support.
• the aggregates are formed by microspheres whose diameter is between 5 and 10 microns.
• the aggregates preferably form the primary network of the hydrogel matrix.
• the aggregates are fixed to each other by fixing points which allow the displacement of one aggregate with respect to another.
• the section progresses increasingly from one end to the other and the section is substantially circular perpendicular to the length of the aggregate.
• the grape-cluster conformation is more advantageous than the linear configuration to facilitate interactions between the cells and the implant and thus facilitate the formation of a multicellular tissue structure and / or the growth of nerve fibers.
• the cluster conformation also improves grip
• the microspheres are fixed to each other by deformable crosslinking points to allow the microbeads to move between them and to adapt the conformation of the hybrid heterogeneous hydrogel support according to the mechanical constraints applied.
• the aggregate can compress. Polymer chains deform between the crosslinking points as they stretch. The crosslinking points move away from each other which results in an increase in the pore fraction of the hydrogel.
• the total pore volume of the implant increases at constant volume in an anisotropic configuration.
• the microbead aggregates are mounted mobile with respect to each other so as to allow the contraction of the microbead aggregates in response to the capillary pressure exerted by the migrating cells in contact with the surface of the microbeads.
• the microbead aggregates are configured so that their contraction results in an expansion of the pore network and an increase in the pore volume available for expansion of the forming tissue.
• the aggregates are attached to each other to form a porous network comprising mesoporous and macroporous domains.
• the multiple pores defined by the aggregates are connected together to form a network percolant which presents a certain tortuosity and which passes through the hydrogel in its initial configuration.
• the percolating network allows the infiltration of cells, blood vessels and nerve fibers through the hydrogel in three dimensions of space during the process of bioreconstruction of the tissue.
• the microspheres define micropores the size of which is less than 20 nm, preferably the size of which varies in the range of 1.5 and 11 nanometers with an average diameter of 6 nanometers. These micropores are closed and not communicating.
• micropores form craters on the surface of the microbeads, which gives the hydrogel microbeads a dimpled surface. These micropores create surface area and help increase the internal specific surface area of the macromolecular network of the hydrogel formed from these hydrogel microbeads. This increase in the surface area of the macromolecular network and the surface topography of the microbeads promote interactions with cell membranes, in particular focal adhesions of migrating cells.
• the percolating network defines a large internal specific surface area, at least equal to 25 m 2 / g, advantageously at least 50 m 2 / g.
• the difference in degree of crosslinking can be defined by means of the manufacturing process used. It is preferable to use a copolymerization of the hydrogel by means of a method which implements a phase separation of the reaction mixture, it is also advantageous to carry out a copolymerization process in which the phase separation comes from thermally induced polymerization. It is particularly advantageous to control the phase separation by carrying out the crosslinking within a defined temperature range. For example, good results have been obtained with a phase separation between 40 ° C and 60 ° C. A more efficient support was obtained with a crosslinking of between 45 ° C and 55 ° C. An even more efficient support was obtained with a crosslinking of between 49 ° C and 51 ° C. The use of such a temperature range makes it possible to better define the dimensions of the microbeads.
• the crosslinking time is greater than 6 hours or even greater than 12 hours to form an implant.
• the hydrogel is formed by strongly crosslinked aggregates linked together by weakly crosslinked areas.
• the strongly crosslinked aggregates form mechanical support areas which can move relative to each other by means of the weakly crosslinked areas.
• the crosslinking points between the aggregates are formed by covalent bonds, that is to say chemical bonds that can be considered as non-degradable, which allows good mechanical strength between the aggregates. It is advantageous to provide that the aggregates are distributed in a statistical manner in the volume of the hydrogel defining areas of high concentration of polymer chains and domains of low concentration of polymer chains and forming cavities containing free water.
• the average distance between two crosslinking points in the highly crosslinked areas is less than 20% of the average distance between two crosslinking points in the weakly crosslinked areas, preferably less than 10% of the average distance between two crosslinking points in the weakly crosslinked areas.
• the proportion of the high crosslinking zone represents at least 60% of the total intrusion volume of the hydrogel. It is also interesting that the proportion of the high crosslinking zone represents less than 80% of the total intrusion volume of the hydrogel.
• the implant surface is not flat. It has defects, for example protuberances from the assembly of the microbeads.
• the microbeads comprise at least 90% by weight or even at least 95% by weight or consist of the acrylamide compound, for example of N-substituted methacrylamide or N-substituted acrylamide in order to confer properties.
• elastic properties to the microbeads ensuring the deformation of the implant with the cellular load.
• the microspheres predominantly or exclusively in acrylamide compound have a diameter of 1.5 and 10 microns, preferably between 2 and 5 microns.
• the microbeads mainly contain HPMA by mass, preferably highly crosslinked HPMA.
• a highly crosslinked microbead has a degree of crosslinking greater than 1 mol% of crosslinking agent.
• the use of such a degree of crosslinking ensures the existence of a sufficient number of chemical crosslinks between the chains of linear polymers per unit volume of the hydrogel.
• This configuration gives the hydrogel sufficient cohesion of the polymer networks, for example HPMA, for an equilibrium swelling rate of 96% of the final mass (g of water / g of dry matter). In the present case, this rate is preferably 0.95 mol%.
• More weakly crosslinked material eg HPMA
• HPMA can be used to form the bonds between the microbeads and define the microbead aggregates.
• the through channels of the implant are delimited by microbeads, the functionalized dendrimer monomer of which comprises one or more macromolecular dendritic branches of poly (ethylene oxide).
• the macromolecular dendritic branch of poly (ethylene oxide) is functionalized by one or more active molecules, for example one of the bioactive copolymerizable materials described above. It is then possible to functionalize the surface of the percolating network to facilitate cell reconstruction inside the implant.
• the active molecule is selected from the group consisting of a derivative of complex sugars, derivatives of tissue adhesion peptide or peptide with angiogenic activity, derivatives of nerve regrowth stimulating peptide, derivatives of tissue adhesion peptide. stimulation of cell proliferation and differentiation, a derivative of a polymer conjugate coupled to antibodies directed against lipid derivatives, chemokines of the Stromal-derived factor-1 (SDF-1) class.
• SDF-1 Stromal-derived factor-1
• the acrylamide compound is N- (2-hydroxypropyl) methacrylamide (HPMA) and the dendrimer monomer functionalized with an ethylenic radical comprises functionalized poly (ethylene oxide) dendrimers. at their periphery with bioactive agents conferring bioactive properties for tissue regeneration.
• a hybrid heterogeneous hydrogel can be produced by means of radical copolymerization. The preferred polymerization process is carried out in an organic and advantageously biorgan polar medium, for example an acetone / DMSO mixture.
• the copolymerization is associated with a phase separation induced by polymerization (PIPS).
• PIPS phase separation induced by polymerization
• the molar ratio between the functionalized dendrimer monomer and the crosslinking agent is between 0.1 and 0.8, for example a PEO-MMA / MbisAA ratio of between 0.1 and 0.8.
• the phase separation defines balls which form the microspheres. In the temperature range 45-55 ° C, it is easier to obtain mainly with balls of acrylamide compound whose diameter is between 1.5 and 10 microns.
• This ratio value also allows the formation of a three-dimensional percolating network. It is even easier to control the number of balls generated and the size distribution of the balls by choosing a functionalized dendrimer monomer whose molecular mass is between 6220 g / mol and 23280 g / mol. In this particular range, when the molar mass of the functionalized dendrimer monomer increases, the number of balls increases and the size distribution decreases.
• the process for forming the hybrid heterogeneous hydrogel comprises a first phase of the reaction of the reaction mixture forming insoluble nuclei consisting of polymer chains formed into a ball.
• the reaction mixture is injected into molds 3 of sealed cylindrical shape and heat conductor with a wall 4 made of PTFE in contact with the reaction mixture.
• the reaction mixture may have undergone degassing with argon.
• the microbeads are associated to form the aggregates and the aggregates are linked together to form the heterogeneous hybrid hydrogel intended to form the filling implant.
• the copolymerization is carried out using a crosslinking agent.
• the crosslinking agent can be an acrylamide such as methylene bisacrylamide (MbisAA), precursors thereof or divinyl compounds such as divinylbenzene (DVB).
• the free radical polymerization initiator is selected from known initiators such as azobisisobutyronitrile (AIBN) or benzoyl peroxide.
• the crosslinking agent is preferably methylene bisacrylamide (MbisAA) which has two vinyl groups.
• Methylene bisacrylamide provides superior reactivity compared to N- (2-hydroxypropyl) methacrylamide (HPMA) which has only one vinyl group. This allows for faster incorporation of methylene bisacrylamide into the growing chains which form nuclei before forming the microbeads.
• poly (ethylene oxide) hydrogel It is particularly interesting to use a poly (ethylene oxide) hydrogel because poly (ethylene oxide) has demonstrated a neuroprotective effect on the membrane of neurons and decreases post-lesion oxidative stress (Luo et al. Polyethylene). glycol immediately repair neuronal membranes and inhibits free radical production after spinal cord injury. J. Neurochem. 83, 471, 2002). It is preferable to use a hydrogel formed from one or more polymers with a branched star structure with branches of poly (ethylene oxide) which improves the biocompatibility of the hydrogel in particular by preventing non-specific absorption.
• branched molecules can be modified with functional groups of the class of peptides, bioactive sugars, chemokines by bioconjugation in the terminal position of the poly (ethylene oxide) branches. It is particularly advantageous to form a hydrogel material which has a porous structure formed in a support comprising a structure composed of N- (2-Hydroxypropyl) methacrylamide and a branched structure formed by branched poly (ethylene oxide) polymers carrying functional groups.
• the functional groups are preferably short peptides such as oligopeptides for interaction with the integrin receptors of cells, for example, but not limited to the following sequences, Arg-Gly-Asp, (RGD), Arg-Gly-Asp-Ser ( RGDS), Ile-Lys-Val-Ala-Val (IKVAV).
• oligomers conjugated to one or more sialic acids for example sialyllactose (Neu5Ac-a2,3-Gal-b1, 4-Glc), as well as sulfated oligosaccharides such as HNK1 (S04-3- GlcA i-4Gai i-4GlcNac-R) or fucosylated oligosaccharides, for example Fuc a (1-2) Gal.
• Bioactive agents can also be selected from growth factors which stimulate axon regeneration which includes, but not limited to BDNF ("Brain Derived Neurotrophic Factors”), IGF-1 ("Insulin-like Growth Factor”), NT -3 (“Neurotrophin”), GDNF ("Glial Derived Neurotrophis Factor”); or which stimulates the proliferation of neuronal precursors such as FGF (“Fibroblast Growth Factors”), and EGF (“Epidermal Growth Factor).
• growth factors which stimulate axon regeneration which includes, but not limited to BDNF (“Brain Derived Neurotrophic Factors”), IGF-1 ("Insulin-like Growth Factor”), NT -3 (“Neurotrophin”), GDNF (“Glial Derived Neurotrophis Factor”); or which stimulates the proliferation of neuronal precursors such as FGF (“Fibroblast Growth Factors”), and EGF (“Epidermal Growth Factor).
• PDGF Platelet-derived Growth Factor
• VEGF Vascular Endothelial Growth Factor
• PIGF Porous Growth Factor
• NGF Neve Growth Factor
• TGF Transforming Growth Factor
• Bioactive agents that stimulate the mobilization of precursor stem cells such as the chemokines SDF-1 (Stromal-derived factor-1) which have the capacity to attract endogenous stem cells expressing the CXCR4 receptor and to stimulate the growth of axons during the tissue regeneration, the cytokines G-CSF (granulocyte colony-stimulating factor), GM-CSF (granulocyte-macrophage colony-stimulating factor) or SCF (stem cell factor) and interleukin (IL-8).
• SDF-1 chemokines
• G-CSF granulocyte colony-stimulating factor
• GM-CSF granulocyte-macrophage colony-stimulating factor
• SCF stem cell factor
• IL-8 interleukin
• One embodiment of the hydrogel is advantageously carried out under an inert atmosphere and comprises a hydrogel which combines N- (2-hydroxypropyl) methacrylamide with the crosslinking agent N, N'-Methylenebisacrylamide or N, N'-Methylenebismethacrylamide comprising two vinyl groups in a molar ratio of 100: 1 to 30.4% by weight of the total weight of the reaction mixture; a polar bi-organic acetone / DMSO solvent (93/7 v / v).
• the reaction mixture is degassed with argon and injected into sealed cylindrical molds which conduct heat with a PTFE wall in contact with the reaction mixture.
• the initial reaction mixture is placed in a metal mold, preferably of stainless steel, the internal walls of which are covered with a polytetrafluoroethylene (PTFE).
• PTFE polytetrafluoroethylene
• the reaction mixture is purged with inert gas directly inside the mold.
• the mold has a circular section with a height at least twice the diameter.
• the use of a metal mold facilitates its use with a water bath which sets the temperature of the mold and the reaction mixture during polymerization. This configuration allows better control of the dimensions of the microspheres and of the pores.
• a radical polymerization reaction preferably in the presence of the initiator azobisisobutyronitrile at 50 ° C. is carried out. It has been observed that it is particularly advantageous to increase the temperature of the mold and of the reaction mixture by at least 5 ° C, preferably by 10 ° C or more during processing. polymerization. It is advantageous if the temperature increase is less than 20 ° C. It is also advantageous for the maximum polymerization temperature to be less than 70 ° C. and even more preferably less than 65 ° C. so as not to degrade the xerogel, that is to say the hydrogel before it is saturated with water. This increase in temperature makes it possible to obtain a more homogeneous distribution of the polymer chains in the hydrogel as well as a better yield.
• the temperature increase is carried out after the formation of the microbeads or of a majority of the microbeads.
• the temperature increase can take place at least after 80 minutes of polymerization, even more preferably after 90 minutes of polymerization.
• the polymerization can be carried out with a first temperature plateau used to form the microbeads, for example a temperature plateau of between 45 ° C and 55 ° C, preferably equal to 50 ° C.
• the temperature plateau is then followed by a second plateau or possibly by a ramp or other form of annealing at a temperature at least 5 ° C higher than the temperature of the plateau.
• the use of two different temperature ranges allows better control of the dimensions of the microspheres and better control of the dimensions of the aggregates.
• the polymerization is carried out until the concentration of oligomers reaches a threshold value making it possible to form longer chains by condensation of the oligomers.
• the condensation of the oligomers induces the appearance of at least two phases having different densities. It is advantageous to carry out phase separation by modifying the polymerization temperature.
• a second polymerization step is carried out at a higher temperature, preferably with a second plate which is at least 5 ° C. hotter than the previous plate. The second plate makes it possible to carry out the copolymerization by accelerating the nucleation and allowing the polymerization to continue.
• Crosslinked oligomer balls are formed which form the microbeads.
• the microspheres aggregate randomly and crosslinking points are formed.
• the absorbance value decreases.
• the second plate is replaced by a ramp or a more complex evolution of the temperature and which has a minimum temperature greater than the temperature of the first plate of at least 5 ° C.
• the mold 3 it is preferable to close the mold 3 in a leaktight manner, for example by means of a polytetrafluoroethylene cover advantageously associated with a gasket 5.
• a polytetrafluoroethylene cover advantageously associated with a gasket 5.
• the use of the cover limits the evaporation of solvents from the reaction mixture and allows better reproducibility.
• the dimensions of the mold are chosen so that the hydrogel formed from the mold has a diameter equal to 175mm and a height equal to 400mm for a hydrated gel. It is also advantageous to use the same metal part which defines several molds in the form of several wells 6.
• the mold 3 may include orifices 7 intended to cooperate with screws to close the wells 6.
• the xerogel is in a dry or anhydrous form and is demolded. It is particularly advantageous to cover the internal walls of the mold with polytetrafluoroethylene because this allows easier demolding of the hydrogel in dry form, which avoids damaging it.
• the xerogel present in the mold is friable, which makes it a fragile material which is easily degraded when it is sought to extract it from the ampoules used in the processes of the prior art. Washing of the xerogel in non-pyrogenic ethanol / water is carried out, which allows it to achieve a swelling rate at equilibrium of 96%. Alternatively, ethanol is replaced by methanol.
• the xerogel is transferred into a first container in the form of a perforated basket, the basket is advantageously made of polytetrafluoroethylene.
• the first basket is installed in a second basket which contains a liquid.
• the liquid can be water, ethanol or methanol or a mixture of water with ethanol or methanol. Liquid from the second container passes through the holes in the first container to clean the xerogel.
• the second container is particularly advantageous for the second container to be opaque to visible radiation.
• the second container can be polycarbonate.
• the xerogel installed in the first container is subjected to a washing cycle which advantageously comprises the application of several successive washing baths.
• the water content is increased in the different baths in order to clean the xerogel and to saturate it with water to form the hydrogel.
• the hydrogel is advantageously crosslinked with methylenebisacrylamide at a rate equal to or substantially also equal to 1 mol% which gives the hydrogel advantageous physical characteristics as a filling implant.
• the gel is conveniently placed in a cylindrical container made of high grade PTFE, a material that does not interact with the chemical nature of the gel, and filled with non-pyrogenic injectable grade water.
• the PTFE container with the gel is sterilized by autoclaving at 121 ° C for 30 minutes and the container is closed with a screw cap tightly to keep the gel water saturated and sterile.
• This container is placed in a second polystyrene container with a "snap safe type cap" which is open on a sterile operating field.
• the second polystyrene container can have a height equal to 54mm, an internal diameter equal to 34mm and a thickness equal to 1.5mm.
• the heterogeneous hybrid hydrogel is advantageously used in a filling strategy in order to modify the natural healing phenomena by carrying out the filling by a regeneration phenomenon in the presence of a viscoelastic matrix which has the property of changing the configuration of its geometric pore space. and the configuration of its polymer network.
• the elasticity effects of the hydrogel offer the advantage of being able to modify the mechanical-elastic properties of the substrate and reconstitute a mechanical environment close to that of cells in vivo.
• Such a hydrogel is able to receive and guide flows of cells, nerve fibers and blood vessels.
• the heterogeneous hybrid hydrogel defines an elastically deformable and continuous porous medium, non-degradable and non-bioresorbable with a geometry that adapts to the kinetics of cell, vascular and nerve regeneration.
• the hydrogel matrix binds to the spinal cord which allows the hydrogel matrix to follow the movements of the spinal cord caused by the movements of the spine and by the beating of the arteries that supply this blood. organ and therefore remain anchored to the graft site.
• the implant forms a support structure, thanks to its open porous structure which allows the flow of cells to migrate into the polymer matrix following the percolating paths of the porous network.
• the hybrid heterogeneous hydrogel forms an implant in a graft cavity, for example an intramedullary cavity.
• the cavity can be formed by dissection and removal of non-living scar tissue from an inner edge of the lesion.
• the edges of the cavity are formed by healthy nerve tissue.
• the supply of the cavity is followed by drainage of the cerebrospinal fluid. This makes it possible to create a “de novo” lesion which is equivalent to an acute lesion, which reactivates the inflammatory processes of endogenous cell repair (mobilization of stem cells, budding of the nerve ends, angiogenesis).
• the implantation method also includes a step of filling the post-traumatic cavity with the introduction of the hydrogel into the intramedullary cavity.
• the hydrogel can be cut to fit the shape and geometry of the cavity.
• the hydrogel swells upon contact with the fluids circulating in the cavity until the hydrogel implant is in contact with the entire surface of the cavity so that it forms an integral interface (100%) with the white matter of the intact peri-lesional nervous tissue.
• the hydrogel is able to absorb a significant amount of water and it swells in the presence of water and body fluids containing water. It is advantageous that the hydrogel contains at least 80% by volume of water at equilibrium. It is advantageous to provide the hydrogel with a water content of less than or equal to 75% by volume.
• the implant is dehydrated so as to have a reduction in its volume of between 10% and 30%.
• the implant is introduced into the cavity, preferably an intra-parenchymal cavity, then it is rehydrated to reach at least 95% of its initial volume, preferably 100% of its initial volume. Hydration of the implant to its initial volume can be achieved in less than a minute. Preferably, the volume of the implant with a swelling rate equal to 100% represents between 80% and 100% of the volume of the cavity to be filled.
• the porous surfaces of the implant come into contact with the surfaces of the cavity, which facilitates adhesion. It is advantageous to have a gradient in the rate of dehydration with a more central portion. hydrated than the peripheral portion. Greater dehydration at the surface improves the quality of contact with the wall of the cavity thereafter.
• the implant To promote adhesion of the implant with the walls of the cavity, it is preferable to dehydrate and then hydrate the walls intended to come into contact. It is also preferable to have an implant that comes in the form of a plurality of bunches of grapes formed by microbeads.
• the conformation of the implant with the aforementioned microbeads makes it possible to define a surface roughness with asperities and protuberances. It is advantageous to have a roughness less than or equal to 30 micrometers, preferably less than or equal to 15 micrometers and even more advantageously less than or equal to 5 micrometers. It is also advantageous for the roughness to be greater than or equal to 0.1 micrometer.
• Such a range of roughness helps promote the circulation of interstitial fluids between the surface of the hydrogel and the parenchyma.
• This surface texture comes from the cluster structure of the hydrogel microbeads. Adhesion is also promoted by the surface pores on the protrusions on a nanoscale.
• the implant is particularly suitable for matching the geometry of the surfaces of the cavity. These steps result in the anatomical reconstitution of the spinal cord at the level of its traumatic zone. It is particularly advantageous to cover the implant with living peri-lesional white matter comprising the ascending, descending and association nerve fibers to take advantage of the bioadhesive properties of the implant with the biological tissue.
• an implant which has bioadhesive properties or bioadhesive properties. improved. By adapting the properties of the implant surface, this improves the adhesion between the implant and the biological tissue.
• the implant When the implant has improved bioadhesive properties, it can be inserted into the cavity and have quality cell reconstruction without the use of surgical sutures with the biological tissue.
• the implant actively stimulates hemostasis and more particularly the primary phase of hemostasis. It is also advantageous that the implant actively stimulates platelet aggregation. In this way, the implant induces blood coagulation which facilitates the achievement of good tissue reconstruction.
• This particular implant configuration allows micro-bleeding to be controlled as close as possible to the interface between the implant and the cavity, thereby preventing the formation of a degraded interface between the implant and the tissue. In vitro blood coagulation and platelet aggregation tests as well as in vivo tests have shown good control of hemostasis by the implant.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Oral & Maxillofacial Surgery (AREA)
• Transplantation (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Dermatology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Polymers & Plastics (AREA)
• Organic Chemistry (AREA)
• Dispersion Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Materials For Medical Uses (AREA)
• Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
• Compositions Of Macromolecular Compounds (AREA)
• Processes Of Treating Macromolecular Substances (AREA)
• Medicinal Preparation (AREA)
• Graft Or Block Polymers (AREA)
• Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
• Prostheses (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (1)

Family

ID=71452405

Family Applications (1)

Country Status (12)

Cited By (2)

Families Citing this family (1)

Citations (14)

Family Cites Families (6)

• 2020
  • 2020-03-17 FR FR2002619A patent/FR3108260B1/fr active Active
• 2021
  • 2021-03-17 WO PCT/EP2021/056753 patent/WO2021185881A1/fr not_active Ceased
  • 2021-03-17 CN CN202180021887.0A patent/CN115297903B/zh active Active
  • 2021-03-17 EP EP21711292.9A patent/EP4121133B1/fr active Active
  • 2021-03-17 AU AU2021237753A patent/AU2021237753A1/en active Pending
  • 2021-03-17 US US17/912,184 patent/US12599703B2/en active Active
  • 2021-03-17 JP JP2022555660A patent/JP2023518227A/ja active Pending
  • 2021-03-17 CA CA3167699A patent/CA3167699A1/en active Pending
  • 2021-03-17 KR KR1020227035527A patent/KR20220154749A/ko active Pending
  • 2021-03-17 IL IL296328A patent/IL296328B2/en unknown
  • 2021-03-17 BR BR112022017583A patent/BR112022017583A2/pt unknown
  • 2021-03-17 MX MX2022011096A patent/MX2022011096A/es unknown

Patent Citations (18)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events